sulfotransferase family 1A member 3Genealiases: HAST · HAST3 · M-PST · ST1A3 · ST1A3/ST1A4 · ST1A4
Q-omics provides the consensus-scored SULT1A3 profile across patient tissues and cancer cell-line models. SULT1A3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SULT1A3 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, SULT1A3 RNA expression shows 13,029 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where SULT1A3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SULT1A3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SULT1A3 survival associations across molecular data types. SULT1A3 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SULT1A3 RNA expression–survival associations across cancer types. High SULT1A3 expression shows unfavorable associations in KIRC, KIRP, COAD and LGG, but favorable associations in BLCA and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SULT1A3 RNA expression.
This table summarizes SULT1A3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SULT1A3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SULT1A3 shows higher tumor expression in KIRC, BLCA, STAD, LUAD, LUSC and LIHC. The KIRC box plot shows higher SULT1A3 RNA expression in tumor versus normal tissue (log2 FC = +0.030, t-test p < 0.001).
This table shows molecular features associated with SULT1A3 in patient tissues and cancer cell lines. In patient samples, SULT1A3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SULT1A3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
